Identification of cellular targets involved in cardiac failure caused by PKI in oncology: an approach combining pharmacovigilance and pharmacodynamics.

Emilie Patras de Campaigno Emmanuelle Bondon-GuittonGuy LaurentFrançois MontastrucJean-Louis MontastrucMaryse Lapeyre Mestre Fabien Despas

Published in: British journal of clinical pharmacology (2017)

We observed a higher disproportionality for CF with dasatinib, imatinib, bosutinib, sunitinib and nilotinib than with other PKIs. In addition, the study highlighted the role of ABL tyrosine kinases in CF caused by anticancer PKIs.

Keyphrases

chronic myeloid leukemia
cystic fibrosis
palliative care
left ventricular
adverse drug
emergency department
renal cell carcinoma
heart failure
drug induced
tyrosine kinase